We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Members need only apply.
- Abstract
The author discusses the Innovative Medicines Initiative (IMI) funding of 154 million euros launched in Europe for academics, intergovernmental organizations and small-to medium-sized enterprises (SMEs). The author agrees that funding can help boost the European pharmaceutical sector along with emphasis on intellectual property (IP) as biotech company asset. An overview of the plan of European Federation of Pharmaceutical Industry Associations (EFPIA) members to pool their resources is given. The author suggests more work for engaging biotech SMEs.
- Subjects
EUROPE; STUDY &; teaching of medicine; INTERNATIONAL agencies; PHARMACEUTICAL industry; BIOTECHNOLOGY
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 7, p551
- ISSN
1087-0156
- Publication type
Editorial
- DOI
10.1038/nbt.1922